Navigation Links
Daiichi Sankyo Completes Enrolment in Hokusai - VTE, investigating once-daily Edoxaban in the Largest Single Phase 3 Study for the Treatment and Prevention of Recurrence of VTE
Date:10/25/2012

TOKYO, Oct. 25, 2012 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has completed patient enrolment in the global Hokusai-VTE phase 3 study investigating the once-daily oral factor Xa inhibitor edoxaban for the treatment and prevention of recurrence of venous thromboembolism (VTE) in patients who have had an acute symptomatic deep vein thrombosis (DVT), pulmonary embolism (PE), or both.1,2

Hokusai-VTE is the largest single phase 3 clinical study in the treatment and prevention of recurrence of VTE. More than 8,250 patients have been enrolled in the trial from more than 400 clinical sites across 38 countries worldwide.1,2

The Hokusai-VTE clinical study has been designed to reflect clinical practice, using a standard heparin lead-in, and providing a flexible treatment duration of three, six or 12 months. Edoxaban 60mg once-daily will be compared to warfarin control therapy (target INR 2-3).2   This study design is allowing investigators to evaluate patients with a broad range of risks, including patients with moderate or severe conditions of PE and DVT.1,3,4

"With its rigorous design and large patient population, Hokusai-VTE marks an important step in the development of the new class of oral anticoagulants, direct factor Xa inhibitors," said Professor Harry Buller, MD, PhD, Professor of Internal Medicine, Chairman of the Department of Vascular Medicine at the Academic Medical Center in Amsterdam, The Netherlands and Chairman of the Hokusai-VTE steering committee. "What sets the Hokusai-VTE study apart from other studies of its kind is that it aims to reflect clinical practice through the flexible treatment duration." 

Edoxaban is an investigational once-daily, novel oral anticoagulant that specifically, reversibly and directly inhibits factor Xa, which is an important factor in the coagulation system that leads to blood
'/>"/>

SOURCE Daiichi Sankyo
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Daiichi Sankyo, Inc. Receives FDA Approval to Package Product at New Facility in Bethlehem, PA
2. HeartWare Completes Enrollment In 450-Patient Pivotal Destination Therapy Clinical Trial
3. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
4. NuMe Health Completes $1.5 Million Series A Financing To Advance Its First Cobiotic™ Aimed At Helping Prediabetics Maintain Healthy Blood Glucose Levels
5. CryoLife Completes Acquisition of Hemosphere
6. Bausch + Lomb Completes the Acquisition of ISTA Pharmaceuticals
7. Savara Pharmaceuticals Completes Phase I Clinical Study of AeroVanc in Cystic Fibrosis Patients
8. Jazz Pharmaceuticals Completes EUSA Pharma Acquisition
9. Amgen Completes Acquisition of Mustafa Nevzat Pharmaceuticals
10. Ablative Solutions Completes $5.3M Series A Financing
11. Quantum OPS Completes $1.05M In Series A Financing To Advance Surgical Devices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... baseball,s all-time hits leader, is the new spokesperson for the ... has announced. "Pete,s a Hall of Famer in ... board with Myoflex," said Ducere Pharma Chief Executive Officer ... known across all generations. The passion and intensity that Pete ...
(Date:1/23/2015)... EAST SETAUKET, N.Y. , Jan. 23, 2015  Lixte Biotechnology ... sites where its Phase I trial of Lixte,s lead compound, ... 5 institutions. John S. Kovach , M.D., ... trial was planned to be completed at a single site. ...
(Date:1/23/2015)... , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... has approved a share repurchase program. The open-ended authorization ... of Mallinckrodt plc ordinary shares. "Funding ... top priorities as we continue to pursue a range ...
Breaking Medicine Technology:Pete Rose bets on Myoflex to relieve aches and pains 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4
... According to Millennium Research Group (MRG), the global authority ... 2003 in Brazil, Russia, India, and China (BRIC) has ... astounding $500 billion spent in 2009 alone. One effect ... from MRG,s newest series of global diagnostic imaging reports ...
... Eclipsemed Ltd, a leading national supplier of advanced medical ... Human Med USA. Human Med AG of Germany, ... the revolutionary Body-Jet®, has formed Human Med USA to ... in the United States and North America. , ...
Cached Medicine Technology:$500 Billion Health Care Spend Boosts BRIC Countries' Diagnostic Imaging Sales Despite Global Recession, According to Millennium Research Group 2$500 Billion Health Care Spend Boosts BRIC Countries' Diagnostic Imaging Sales Despite Global Recession, According to Millennium Research Group 3Eclipse Announces Partnership with Human Med USA, Manufacturers of Revolutionary Body-Jet(R) 2
(Date:1/22/2015)... the premier women’s dress supplier, has recently released its ... of AngelWeddingDress.com to find more details. , Many ... a bridal party. AngelWeddingDress offers a variety of gorgeous ... wedding dresses are specially designed for 2015. , AngelWeddingDress ...
(Date:1/22/2015)... A new white paper by The ... in the long-term care environment as well as provides ... The paper, “The Power of Person-Centeredness in Long-Term Care: ... of the patient, resident and family experience in long-term ...
(Date:1/22/2015)... Oceanside,CA (PRWEB) January 22, 2015 For over 20 ... the Oceanside and Vista area has treated just about ... other personal injury circumstances. And for those same twenty-plus years, ... victims of all those injuries with the best possible doctor. ...
(Date:1/22/2015)... New York, NY (PRWEB) January 22, 2015 ... American College of Sports Medicine flagship journal Medicine ... supplementation with L-Citrulline before exercise may help reduce ... strenuous exercise. 1 , Participants in the ...
(Date:1/22/2015)... 22, 2015 IsoComforter, Inc. has introduced the ... patented IsoTube design to treat specific body parts and muscle ... progressive and easy to use patented cold therapy machine with ... related orthopedic and muscle injuries. IsoComforter has become the ...
Breaking Medicine News(10 mins):Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2
... following is a statement by Governor Lowell Weicker, Jr., ... President of the Board of the Trust for America,s ... Hamburg, MD, to serve as Commissioner of the Food ... as a TFAH Board Member for the past five-and-a-half ...
... involvement in health care recruiting and staffing. Individuals have the choice ... or working with an established Health Career Agents office. , ... ... Career Agents now has three ways for qualified individuals to get ...
... and futurist Ray Kurzweil , described by Forbes ... Sen. Tom Harkin (D-IA), health and wellness expert ... PepsiCo Senior Vice President and Chief Scientific Officer Dr. Mehmood ... March 16th conference on Race and Reconciliation in America: ...
... is underutilized in the U.S., expert says, , , FRIDAY, ... that people with chronic kidney disease, whether young or ... (AV) fistulas, surgically created passageways between veins and arteries ... , In calling AV fistulas the "gold standard of ...
... Plastic and Reconstructive Surgeon Kouros Azar, M.D. ... National Patient Safety Awareness Week from March 8 to 14, ... Massachusetts. Patient safety and comfort are paramount to Dr. ... foot state-of-the-art facilities located at 425 Haaland Drive, Suite 200 ...
... 1st new drug for disease in 50 years , , FRIDAY, ... offer the first new treatment approved for lupus in 50 ... College London. , The 22-month study included 20 people ... disease lupus. After treatment with Rituxan, 60 percent showed significant ...
Cached Medicine News:Health News:Appointment of Margaret Hamburg to Lead FDA Lauded by Gov. Lowell Weicker, President of the Board of Trust for America's Health 2Health News:Health Career Agents Announces Three Options for Involvement in Health Care Recruiting and Staffing 2Health News:Health Career Agents Announces Three Options for Involvement in Health Care Recruiting and Staffing 3Health News:Chopra, Harkin, Kurzweil, Ornish, Khan Top Race & Reconciliation Conclave on Health and Wellness 2Health News:Chopra, Harkin, Kurzweil, Ornish, Khan Top Race & Reconciliation Conclave on Health and Wellness 3Health News:Chopra, Harkin, Kurzweil, Ornish, Khan Top Race & Reconciliation Conclave on Health and Wellness 4Health News:Dialysis Via Fistulas May Help Young or Old 2Health News:Kouros Azar, M.D. (doctorazar.com), Noted Plastic and Reconstructive Surgeon, Offers Top 10 Tips to Patients to Help Celebrate National Patient Safety Awareness Week 2
The Medmont C100 Colour Vision Tester is an electronic colour vision screening device which is used to rapidly detect red/green colour vision deficiencies. Its high sensitivity provides a positive in...
... test capability extending to 80, the M700 ... visual field, allowing peripheral defects that are ... be explored. Practice Management Integration provides the ... the Medmont Studio package the practitioner is ...
... The new software upgrade including fourSight ... Antares ultrasound system offers a wide variety ... added data management features that combine to ... challenges. , ,The Antares system was built ...
... stent technology with no compromises. It's the ... results. With S670's discrete, low-profile delivery system, ... excellent clinical results you want. S670, the ... compromises. It's the stent that delivers like ...
Medicine Products: